⌘K
t
Venture Life Group PLC granted 1,000,000 options to subscribe for ordinary shares to Peter Jackson, its Chief Digital and Technology Officer. These options, granted on 1 December 2025, have an exercise price of 58.76p each and will vest after three years following the publication of the Company's annual results for 2028, subject to certain performance criteria.
| Date | 12 Mar 2026 |
| Time | 14:11:15 |
| Category | Director/PDMR dealings |
| ID | 4588W |
12 March 2026
VENTURE LIFE GROUP PLC
("Venture Life", "VLG" or the "Group")
Grant of Options and Director Dealing
Venture Life Group PLC (AIM: VLG), a recognised leader in proactive healthy, product innovation, development, and commercialisation within the global consumer healthcare sector, announces that, pursuant to the Company's 2023 Long Term Incentive Plan ("LTIP"), it has granted options to subscribe for 1,000,000 ordinary shares of 0.3p each in the capital of the Company at an exercise price of 58.76p (the "Options") to Peter Jackson, Chief Digital and Technology Officer on 1 December 2025.
The Options, which are subject to malus and clawback provisions, will vest after three years following publication of the Company's annual results for 2028 and will be exercisable within 7 years of vesting. Vesting is conditional on the achievement of certain performance criteria which include a total shareholder return and earnings per share measurement.
For further information, please contact:
Venture Life Group PLC +44 (0) 1344 578004
Jerry Randall, Chief Executive Officer
Daniel Wells, Chief Financial Officer
Cavendish Capital Markets Limited (Nomad and Broker) +44 (0) 20 7720 0500
Stephen Keys/George Lawson (Corporate Finance)
Michael Johnson (Sales)
About Venture Life (www.venture-life.com)
Venture Life is an international consumer self-care company focused on commercialising products for the global self-care market. Headquartered in the UK, the Group's product portfolio includes Balance Activ in the area of women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, plus the Health & Her product range supporting the hormonal lifecycle.
The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through health & beauty stores, pharmacies, grocery multiples and e-commerce channels and are sold globally. In the UK, Ireland and the USA these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018), provide further detail on the share dealings.
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
|||||
|
a)
|
Name
|
Peter Jackson |
||||
|
2
|
Reason for the notification
|
|||||
|
a)
|
Position/status
|
Chief Digital and Technology Officer |
||||
|
b)
|
Initial notification /Amendment
|
Initial notification |
||||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|||||
|
a)
|
Name
|
Venture Life Group plc |
||||
|
b)
|
LEI
|
213800S8CZUPLAB2KC70 |
||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|||||
|
a)
|
Description of the financial instrument, type of instrument
Identification code
|
Ordinary Shares of 0.3p each in Venture Life Group plc
GB00BFPM8908 |
||||
|
b)
|
Nature of the transaction
|
Grant of share options |
||||
|
c)
|
Price(s) and volume(s)
|
|
||||
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
N/A
|
||||
|
e)
|
Date of the transaction
|
1 December 2025 |
||||
|
f)
|
Place of the transaction
|
London Stock Exchange
|
||||